Clinical trials: Cancer of Nasopharynx
Nasopharyngeal Carcinoma
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other…
- Trial name
- NCT00431210
- Testing
- Epstein-Barr virus-specific adoptive T-cells immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Dana-Farber Cancer Institute
Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II…
- Trial name
- LIGHT (NCT07325539)
- Testing
- Gemcitabine(GEM), Cisplatin, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Mucositis Oral
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy.
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Trial name
- NCT00293462
- Testing
- sargramostim, oral salt and soda mouthwash
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Marilyn Dodd
Nasopharyngeal Carcinoma
Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma
Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03932266
- Testing
- Endostar, Cisplatin, Docetaxel
- Volunteers
- 73 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Effects of Chemotherapy
The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma
The study is designed to compare Intensity Modulated Radiotherapy (IMRT) in combination with concurrent chemotherapy and IMRT alone in treatment of stage II nasopharyngeal carcinoma.
- Trial name
- NCT02116231
- Testing
- Concurrent chemotherapy with cisplatin, Intensity modulated radiotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Nasopharyngeal Cancer
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01074021
- Testing
- Nimotuzumab
- Where
- 24 sites in China
- Volunteers
- 480 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
This study aims to explore a new, more effective and tolerable treatment regimen for patients with advanced recurrent/metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05854849
- Testing
- Camrelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898664
- Testing
- cytogenetic analysis, gene expression analysis, mutation analysis
- Volunteers
- 74 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Nasopharyngeal Carcinoma (NPC), Recurrent Nasopharyngeal Neoplasms
Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
This single-arm, single-center phase II trial evaluates the safety and efficacy of a non-continuous radio-immunotherapy strategy for recurrent nasopharyngeal carcinoma (NPC) unsuitable for surgery.
- Trial name
- REDEFINE (NCT07277764)
- Testing
- High-Low Dose Radiotherapy
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
This is a single-arm, multi-center, open-label, phase II trial to examine the efficacy of pembrolizumab for prolonging the one-year disease free survival in nasopharyngeal carcinoma patients with solely detectable EBV DNA after…
- Trial name
- NCT03544099
- Testing
- Pembrolizumab
- Where
- 8 sites in Taiwan
- Volunteers
- 2 people
- Sponsor
- National Health Research Institutes, Taiwan
Nasopharyngeal Carcinoma
NBI to Detect Post-RT Mucosal Residual NPC
NBI has been proven to be a useful tool to detect early NPC, but they were few studies concerning the detection of post-radiotherapy mucosal residual NPC using NBI system
- Trial name
- NCT02584790
- Testing
- Laryngoscope with NBI system
- Where
- Hong Kong
- Volunteers
- 55 people
- Sponsor
- Pamela Youde Nethersole Eastern Hospital
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
The purpose of this study is to investigate how effective the study drug IPI-549 is against types of cancers. IPI-549 is considered experimental because it is not approved by the US Food and Drug Administration (FDA) for the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Cancer Stage IV
- Trial name
- NCT03795610
- Testing
- IPI-549
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Assuntina G. Sacco, MD
Toxicity Due to Radiotherapy, Nasopharyngeal Carcinoma
Clincal Study of Reduced Target Radiotherapy in Nasopharyngeal Carcinoma
To determine whether subtractive radiotherapy can significantly reduce the acute side effects of radiotherapy and improve the quality of life of patients on the basis of ensuring the existing curative effect.
- Trial name
- NCT05741008
- Testing
- Target range
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Kunming Medical University
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
This is a Phase III trial to study the effectiveness of nimotuzumab versus cisplatin combined with intensity-modulated radiation therapy (IMRT) in treating patients with stage II-III nasopharyngeal carcinoma.
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
- Trial name
- NCT03837808
- Testing
- Nimotuzumab, Cisplatin
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms
Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma
The purpose of this study is to compare individualized clinical target volume (CTV) based on disease extension risk atlas and computer-aided delineation with traditional CTV in intensity modulated radiotherapy (IMRT) for…
- Trial name
- NCT02627807
- Testing
- IMRT using individualized CTV, IMRT using traditional CTV, Gemcitabine and cisplatin (induction chemotherapy)
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Sun Yat-sen University
Neurocognitive Impairment, Delirium
Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic
RATIONALE: Gathering information about how often problems with neurocognitive functioning occur in patients with newly diagnosed upper aerodigestive tract cancers may help doctors learn more about the disease.
- Conditions
- Neurocognitive Impairment, Delirium, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00533884
- Testing
- Assessment of therapy complications, Neurocognitive assessment, Quality-of-life assessment
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Vanderbilt University Medical Center
Nasopharyngeal Carcinoma, Surgery
Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
The goal of this clinical trial is to compare the efficacy and safety of endoscopic nasopharyngectomy combined with retropharyngeal lymph nodes dissection plus bilateral upper neck lymph node dissection or plus postoperative…
- Conditions
- Nasopharyngeal Carcinoma, Surgery, Radiotherapy
- Trial name
- NCT06688760
- Testing
- Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Low Dose Radiotherapy, Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Double upper neck lymph node dissection
- Where
- 2 sites in China
- Volunteers
- 86 people
- Sponsor
- Ming-Yuan Chen
Nasopharyngeal Carcinoma
Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma
This is a randomized parallel control trial to evaluate whether radical loco-regional Radiotherapy can prolong survival time of initial untreated metastatic nasopharyngeal carcinoma.
- Trial name
- NCT02111460
- Testing
- Loco-regional Radiotherapy
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
This study is a multicenter, randomized, controlled phase III clinical trial aiming to investigate the efficacy and safety of Becotatug Vedotin induction therapy followed by concurrent chemoradiotherapy (CCRT) combined with…
- Trial name
- NCT07459296
- Testing
- Becotatug Vedotin, Sintilimab, Cisplatin
- Where
- China
- Volunteers
- 266 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.